News · Branded ingredient · 2026-11-09

Own research, oral and topical: Techinno Health's urolithin A update

Urolithin A is now a closely watched ingredient in international supplements and premium skincare. The more public research there is, the harder it is to stand apart. Techinno Health's approach: spend more than two years on its own research question, then follow a path from research evidence to formulation to finished-product solutions, building one oral and one topical ingredient line.

Own research: starting from proteostasis

Proteostasis is one of the widely used hallmarks of ageing. Cells depend on ribosomes and new protein synthesis to stay in good working order. Techinno Health made one question its core research direction: can urolithin A support ribosome biogenesis and new protein synthesis?

In cell models including AC16 cardiac and AML12 liver cells, oxidative stress, cell-cycle arrest or glycation-related stress lowered the new-protein signal to about 20–35% of control; 5 µM MitoIgnite® urolithin A raised it about two- to three-fold. These are company-reported cell results, not a human effect. Techinno Health filed a PCT international patent application on this direction in October 2026.

MitoIgnite® HPG-labelled new protein synthesis in AC16 and AML12 cell models

HPG-labelled new proteins (green) and nuclei (blue). Source: Techinno Health company-reported cell experiments.

Urolithin A and ribosomes: MitoIgnite® cell data

Oral: MitoIgnite® and the TI-3N® combination

Oral-grade MitoIgnite® urolithin A is ≥99% pure (HPLC on every batch). At formulation level, Techinno Health studied TI-3N®, a three-ingredient combination of urolithin A, fisetin and ergothioneine.

In UVB-induced senescent human skin fibroblasts (BJ), about 80% of cells were senescence-positive (SA-β-gal). None of the three ingredients alone produced a significant drop, any two together brought it to about 60%, and all three together to about 20% (p<0.0001). The Chinese patent application CN120078657A is published, and the PCT application has been internationally published (WO2026179956A1).

TI-3N® composition, original patent figure: SA-β-gal, p21 and p16

TI-3N® composition, original patent figure: SA-β-gal, p21 and p16. Source: CN120078657A.

Topical: two MitoYouth® grades

Low water solubility, poor dispersion and unstable systems have long held back topical use of urolithin A. Topical-grade MitoYouth® urolithin A follows a route from dispersion to stability to delivery to finished-product testing, and comes in two grades.

MitoYouth® WS, water-dispersible: urolithin A ≥10% on a hydrophilic carrier, preservative-free, added directly to the water phase at 1–5%; in commercial production.

MitoYouth® 80% powder: for oil-phase and solid systems at 0.1–1%; confirm the dispersion process and finished-product compatibility for each system.

MitoYouth® has completed China's new cosmetic ingredient filing (filing no. 国妆原备字20250106, INCI: Urolithin A), a 30-subject human patch test (0 adverse reactions) and a nine-item safety dossier.

Industry salon at CIIE

On 7 November 2026, Kelly Yang, Head of Scientific Affairs at Techinno Health, joined the sixth industry salon held during the China International Import Expo (theme: medical and research co-creation), speaking with clinical, research and industry representatives about global resource co-creation and the internationalisation of Chinese beauty innovation.

Every claim, backed by evidence

Techinno Health's vision is to help people live ten years younger. With full-service capability from ingredient and mechanism to formulation and finished product, Techinno Health studies urolithin A in depth and puts it to work, using its own research and data to bring branded ingredients to global markets with its partners.

Specifications, COAs and samples: ty-sales@taiyi-nb.com

This article shares ingredient information for business customers. It is not an efficacy claim, medical advice or legal opinion. Cell results are early findings and do not equal a human effect.

All news